Collegium Pharmaceutical

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell COLL and other ETFs, options, and stocks.

About COLL

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR, Belbuca, and Symproic. 

CEO
Vikram Karnani
CEOVikram Karnani
Employees
423
Employees423
Headquarters
Stoughton, Massachusetts
HeadquartersStoughton, Massachusetts
Founded
2002
Founded2002
Employees
423
Employees423

COLL Key Statistics

Market cap
1.18B
Market cap1.18B
Price-Earnings ratio
21.49
Price-Earnings ratio21.49
Dividend yield
Dividend yield
Average volume
524.77K
Average volume524.77K
High today
High today
Low today
Low today
Open price
$39.04
Open price$39.04
Volume
0.00
Volume0.00
52 Week high
$50.79
52 Week high$50.79
52 Week low
$23.23
52 Week low$23.23

Stock Snapshot

Collegium Pharmaceutical(COLL) stock is priced at $37.28, giving the company a market capitalization of 1.18B. It carries a P/E multiple of 21.49.

During the trading day, Collegium Pharmaceutical(COLL) stock saw an opening price of $39.04, a peak of —, and a bottom of —.

Trading activity shows a volume of 0, compared to an average daily volume of 524.77K.

Over the past 52 weeks, Collegium Pharmaceutical(COLL) stock has traded between a high of $50.79 and a low of $23.23.

Over the past 52 weeks, Collegium Pharmaceutical(COLL) stock has traded between a high of $50.79 and a low of $23.23.

COLL News

TipRanks 3d
Collegium, Paris Hilton announce ‘Embrace Your Sparkle’ campaign

Collegium Pharmaceutical (COLL) and Paris Hilton announced ‘Embrace Your Sparkle’, a campaign aimed at encouraging broader understanding and open dialogue about...

Simply Wall St 5d
A Look At Collegium Pharmaceutical Valuation After Mixed Q4 2025 Results And Updated 2026 Guidance

Collegium Pharmaceutical (COLL) shares came under pressure after its Q4 and full year 2025 report, where earnings and revenue missed some analyst estimates, whi...

A Look At Collegium Pharmaceutical Valuation After Mixed Q4 2025 Results And Updated 2026 Guidance

Analyst ratings

83%

of 6 ratings
Buy
83.3%
Hold
16.7%
Sell
0%

People also own

Based on the portfolios of people who own COLL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.